15 October 2025
Oncology
...
-
18 March 2026
-
18 March 2026
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
PARIS, FRANCE, 18 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the presentation of new preclinical data across multiple early development programs currently in Phase I clinical trials, at the American Association of Cancer Research (AACR)...
-
15 December 2025
-
15 December 2025
Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline
PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. ...
-
22 October 2025
-
22 October 2025
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
PARIS AND MARSEILLE, FRANCE, 22 October 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) and ImCheck Therapeutics today announced they have entered into a definitive share purchase agreement in which Ipsen will acquire all issued and outstanding shares of ImChec...
-
05 December 2025
- 2 mins read
-
05 December 2025
- 2 mins read
Bold Science, Bold Ambition: Shaping the Future of Oncology at Ipsen
Ivan Diaz-Padilla, Senior Vice President and Global Head, Oncology Therapeutic Area Unit, R&D at Ipsen, shares his vision for building a balanced and sustainable pipeline powered by bold science....
-
22 October 2025
- 1 min read
-
22 October 2025
- 1 min read
-
13 October 2025
-
13 October 2025
ESMO 2025: new data reinforces breadth and depth of Ipsen’s growing oncology pipeline and portfolio
PARIS, FRANCE, 13 October 2025 – Ipsen announced today data to be presented at the upcoming European Society of Medical Oncology (ESMO) Symposium on 17-21 October 2025 for rare cancers and complex tumors, offering opportunities to change the course of di...
-
22 December 2025
-
22 December 2025
Ipsen, Université de Montréal and IRICoR expand long-term partnership to accelerate early-stage oncology innovations
PARIS, FRANCE AND MONTREAL, CANADA 22 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), Université de Montréal and IRICoR, of the Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal, announced today a new research coll...
-
25 February 2026
- 2 mins read
-
25 February 2026
- 2 mins read
We’re Ready for ASCO GU 2026: Advancing Knowledge Together
Vanessa Barue, Senior Medical Director, Medical Asset Lead, Global Medical Affairs Oncology...